Dr. Reddy's Laboratories Ltd. (DRREDDY) fundamentals
Dr. Reddy's Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as DRREDDY (ISIN INE089A01031). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Dr. Reddy's Laboratories Ltd. does
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Valuation and market data
| Last close | ₹1165.50 |
|---|---|
| Market capitalisation | ₹96,125 crore |
| Enterprise value | ₹97,734 crore |
| P/E (TTM) | 23.12 |
| Price to book | 2.51 |
| Price to sales (TTM) | 1.59 |
| Book value per share | ₹463.54 |
| Dividend yield | 68.64% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Fri May 30 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹35,059 crore | ₹5,393 crore | ₹4,158 crore | 50.41 |
| Mar 2025 | ₹33,741 crore | ₹7,680 crore | ₹5,725 crore | 67.89 |
| Mar 2024 | ₹28,905 crore | ₹7,201 crore | ₹5,578 crore | 67.04 |
| Mar 2023 | ₹25,725 crore | ₹6,049 crore | ₹4,507 crore | 271.47 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 26.6% |
|---|---|
| Foreign institutions (FII) | 32.1% |
| Mutual funds | 13.2% |
| Other domestic institutions | 18.6% |
| Retail and others | 9.6% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.